Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study

[1]  B. Kiely,et al.  5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) , 2020, Annals of Oncology.

[2]  S. Mathoulin-Pélissier,et al.  Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016. , 2020, European journal of cancer.

[3]  C. Leslie,et al.  ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer , 2020, Nature Genetics.

[4]  C. Curtis,et al.  Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases , 2019, Nature Genetics.

[5]  G. Mills,et al.  Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. , 2019, European journal of cancer.

[6]  E. Winer,et al.  Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  R. Xu,et al.  Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. , 2019, JAMA oncology.

[8]  F. Bertucci,et al.  Genomic characterization of metastatic breast cancers , 2019, Nature.

[9]  B. Taylor,et al.  The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. , 2018, Cancer cell.

[10]  S. Vacher,et al.  Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer , 2018, Breast Cancer Research.

[11]  P. V. van Diest,et al.  Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. , 2018, Cancer research.

[12]  P. V. van Diest,et al.  Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis , 2018, Journal of the National Cancer Institute.

[13]  J. Pérez-García,et al.  The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies. , 2017, Cancer treatment reviews.

[14]  Brent S. Pedersen,et al.  Combating subclonal evolution of resistant cancer phenotypes , 2017, Nature Communications.

[15]  Robert J. Lonigro,et al.  Integrative Clinical Genomics of Metastatic Cancer , 2017, Nature.

[16]  Marie-Cécile Le Deley,et al.  High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. , 2017, Cancer discovery.

[17]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[18]  C. Perou,et al.  Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. , 2017, Cancer research.

[19]  A. Viale,et al.  Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases , 2017, Clinical Cancer Research.

[20]  C. Lefebvre,et al.  Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis , 2016, PLoS medicine.

[21]  M. Cheang,et al.  Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. , 2016, JAMA oncology.

[22]  Lesley Fallowfield,et al.  Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  B. Taylor,et al.  deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution , 2016, Genome Biology.

[24]  Roman Rouzier,et al.  Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials , 2015, Journal of the National Cancer Institute.

[25]  Adrian V. Lee,et al.  Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients , 2015, Clinical Cancer Research.

[26]  Nicolas Servant,et al.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.

[27]  R. Schiff,et al.  ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer , 2015, Nature Reviews Clinical Oncology.

[28]  R. Bast,et al.  Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Andrew Menzies,et al.  Subclonal diversification of primary breast cancer revealed by multiregion sequencing , 2015, Nature Medicine.

[30]  M. Fernö,et al.  Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  T. Fehm,et al.  Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. , 2014, The Lancet. Oncology.

[32]  A. González-Angulo,et al.  Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study , 2014, Breast Cancer Research and Treatment.

[33]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[34]  M. Fernö,et al.  St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases - aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial , 2013, BMC Cancer.

[35]  David Chen,et al.  ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.

[36]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[37]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[38]  O. Nanni,et al.  Hormonal Receptor, Human Epidermal Growth Factor Receptor-2, and Ki67 Discordance between Primary Breast Cancer and Paired Metastases: Clinical Impact , 2012, Oncology.

[39]  A. Thompson,et al.  Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. , 2012, Cancer treatment reviews.

[40]  J. Mefford,et al.  Stromal Genes Add Prognostic Information to Proliferation and Histoclinical Markers: A Basis for the Next Generation of Breast Cancer Gene Signatures , 2012, PloS one.

[41]  J. Bergh,et al.  Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[43]  A. Luini,et al.  Breast cancer subtypes and outcome after local and regional relapse. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  T. Osako,et al.  Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis , 2011, World journal of surgical oncology.

[45]  M. Clemons,et al.  Acquisition of metastatic tissue from patients with bone metastases from breast cancer , 2011, Breast Cancer Research and Treatment.

[46]  A. Thompson,et al.  Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS) , 2010, Breast Cancer Research.

[47]  G. Dranitsaris,et al.  Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  S. Sleijfer,et al.  ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients. , 2017, Cancer treatment reviews.

[49]  M. Somerfield,et al.  Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2015, Journal of oncology practice / American Society of Clinical Oncology.

[50]  M. Fernö,et al.  Gallen molecular subtypes in primary breast cancer and matched lymph node metastases-aspects on distribution and prognosis for patients with luminal A tumours : results from a prospective randomised trial , 2013 .

[51]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[52]  T. Economopoulos,et al.  HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. , 2006, Anticancer research.

[53]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[54]  M. F. Parry,et al.  A Retrospective Analysis , 1990 .